microbiome

Developing a range of products to modify the human
microbiome and bring specific health benefits

RNS & Investor News

Successful Launch of LPLDL® and SlimBiome® products at Vitafoods 2017

16 May 2017

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes announces the successful launch of its SlimBiome® and LPLDL® products at the Vitafoods Europe tradeshow in Geneva from the 9-11 of May 2017. The event provided the opportunity to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. This is viewed as one of the world's leading trade fairs for the food and drinks industry.

OptiBiotix launched the first of its range of heart health products containing LPLDL® called CholBiome and CardioBiome, and its SlimBiome® weight management technology. Both product types were exhibited in the New Products Zone and at Sacco's and Nutrilinea's stands. Sacco and Nutrilinea are OptiBiotix's European manufacturing and formulation partners and have an extensive European network to maximise the commercial opportunity provided by these products.

Both LPLDL® and SlimBiome® were extremely well received with high interest in the distribution and sale of these products from partners across Europe, Japan, India, Asia, Australia and the USA. OptiBiotix's recent appointments, Commercial Director Per Rehne, and Sales and Marketing Director Christina Wood, are leading the commercialisation and internationalisation of these products in global markets. Christina is leading the commercialisation of SlimBiome whilst Per is leading the commercialisation of LPLDL®.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in selling our products. This has already resulted in some companies sending through draft contracts. The Company anticipates that this interest will start to generate revenues from both ingredient supply, and as a component in high value white label and branded formulations and presentations, across multiples territories. We are at the start of the commercialisation process but are really excited at the high level of interest in our products. We look forward to building commercial partnerships, market presence, and multiple revenue streams in both consumer health and pharmaceutical markets around the world."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
   
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0883
Liam Murray  
   
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)  
Tony Quirke (Corporate Broking)  
   
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

back to RNS & Investor News

 

Latest Tweets Twitter

top